

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Kim Richard J</u> (Last) (First) (Middle) C/O INTERCEPT PHARMACEUTICALS, INC. 10 HUDSON YARDS, FLOOR 37 (Street) NEW YORK NY 10001 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>INTERCEPT PHARMACEUTICALS, INC. [ICPT]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>President US Comm & Strat Mktg</u>
	3. Date of Earliest Transaction (Month/Day/Year) <u>10/13/2017</u>	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	10/13/2017		F		84 ⁽¹⁾	D	\$65.49	14,593 ⁽²⁾	D	
Common Stock	01/01/2018		F		552 ⁽¹⁾	D	\$58.42	14,593 ⁽²⁾	D	
Common Stock	01/13/2018		F		89 ⁽¹⁾	D	\$54.95	14,593 ⁽²⁾	D	
Common Stock	02/10/2018		F		1,101 ⁽¹⁾	D	\$54.21	14,593 ⁽²⁾	D	
Common Stock	04/01/2018		F		144 ⁽¹⁾	D	\$61.52	14,593 ⁽²⁾	D	
Common Stock	04/13/2018		F		77 ⁽¹⁾	D	\$73.07	14,593 ⁽²⁾	D	
Common Stock	07/01/2018		F		144 ⁽¹⁾	D	\$83.91	14,593 ⁽²⁾	D	
Common Stock	07/13/2018		F		77 ⁽¹⁾	D	\$97.1	14,593 ⁽²⁾	D	
Common Stock	10/01/2018		F		144 ⁽¹⁾	D	\$126.46	14,593 ⁽²⁾	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date					

Explanation of Responses:

1. Represents shares of common stock withheld to satisfy taxes associated with the vesting of restricted stock.
2. In each case, the amount of securities beneficially owned following the reported transactions is provided as of the date of this Form 4.

/s/ Mark Pruzanski, as attorney-in-fact

10/03/2018

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.